• 1
    Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9: 636642.
  • 2
    Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999;402(Suppl. ):B1217.
  • 3
    Jardieu PM, Fick RB Jr. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999;118: 112115.
  • 4
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108: 184190.
  • 5
    Holgate ST, Chuchalin A, Hébert J, Lötvall J, Chung RF, Bousquet J et al. Omalizumab (Xolair®, RhuMab-E25), a novel therapy for severe allergic asthma [abstract]. Am J Respir Crit Care Med 2001;163(Suppl):A812.
  • 6
    Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18: 254261.
  • 7
    Holgate ST, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17: 233240.
  • 8
    National Institutes for Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NIH Publication no. 97-4051, 1997.
  • 9
    Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol 1997;100: 1622.
  • 10
    Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P et al. Randomised comparison of guided self management and traditional treatment of asthma over one year. BMJ 1996;312: 748752.